Oxidative and Inflammatory Biomarkers As Targets For Novel Therapies – Prof Michael Berk

Posted on: May 22, 2016
Last Updated: January 14, 2020

Professor Michael Berk is currently an NHMRC Senior Principal Research Fellow and Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health, where he heads the IMPACT Strategic Research Centre. He also is an Honorary Professorial Research Fellow in the Department of Psychiatry, the Florey Institute for Neuroscience and Mental Health and Orygen Youth Health at Melbourne University, as well as in the School of Public Health and Preventive Medicine at Monash University. He is a past president of the International Society for Bipolar Disorders and the Australasian Society or Bipolar and Depressive Disorders. He is an ISI highly cited researcher who has published over 800 papers predominantly in mood disorders. His major interests are in the discovery and implementation of novel therapies, and risk factors and prevention of psychiatric disorders.

Author Quotes  

We have a real crisis in drug discovery in our discipline. (psychiatry)

Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia, bipolar disorder, depression and common forms of autism. (Steven Hyman, Former NIMH director)

Every single known risk factor that we have for major psychiatric disorders seems to be transduced through inflammation and oxidative stress.

Cytokine and oxidative stress (Copy)

Summary and slides  

Professor Berk begins his talk with the fact that it has been a long time since any major new discovery was made in pharmaceuticals for psychiatry.  

Taking a look at Eroom’s law (Moore’s law spelt backwards), he presents the rate of decline in pharmaceutical R&D.  

  • Moore’s Law: The number of transistors per square inch on integrated circuits doubles every year since their invention. 
  • Eroom’s Law: The number of drugs discovered halves every year while the cost doubles. 

Continuing, he explains how there are 3 paths currently taken on the road to drug discovery. 

  • Testing a single molecular target based on a sound pathophysiological basis. In psychiatry , however, the pathophysiology of major psychiatric disorders is not known and hence no drugs have been discovered in this way. 
  • Targeting a byway that aims for a biological system or network e.g. oxidative stress and inflammation 
  • Drug discovery through serendipitous clinical findings augmented by clinical observation. This is how most of psychopharmacological discoveries have taken place. 

 Moving on to biomarkers, Prof Berk talks about the holy grail of finding a biomarker for diagnosis. 

He goes on to emphasise how psychiatric disorders appear to be transduced through inflammation and oxidative stress. 

Concluding this video excerpt, Prof Berk presents a fascinating study of how childhood bullying predicts inflammation in adulthood.   

According to the study by Copeland et al.: 

Childhood bullying involvement as either a pure bully or victim predicted changes in CRP levels that lasted into adulthood. Although CRP levels rose for all participants across this period, being bullied predicted greater increases in CRP levels, whereas bullying others predicted lower increases in CRP compared with those uninvolved in bullying. These long-term effects were robust to adjustment for BMI, substance use, childhood physical and mental health status, and exposures to other early-life psychosocial adversities. Inflammation is a plausible mechanism by which bullying involvement may affect short- and long-term health status.

 

Take-home Points:

  • Most drugs to treat psychiatric disorders are discovered serendipitously 
  • Childhood bullying predicts adult inflammation 
  • Psychiatric disorders appear to be transduced through inflammation and oxidative stress 

Learn more

  1. Applications of N-Acetylcysteine (NAC) – From Addiction to Autism By Prof Berk
  2. N-Acetylcysteine (NAC) in Schizophrenia and Bipolar Disorder- Prof Michael Berk
  3. Glutathione, Oxidative Stress and N-Acetylcysteine (NAC) in Psychiatric Disorders – Prof Michael Berk
  4. Effect of the Mediterranean Diet On Depression By Prof Michael Berk
  5. Early Life Nutrition and Neurodevelopment by Prof Michael Berk
  6. The Role of the Microbiome and Diet in Depression by Prof Michael Berk
  7. Healthy Diet vs Nutraceuticals in Depression by Prof Michael Berk
  8. Effect of Diet and Lifestyle Changes in Depression by Prof Michael Berk

References

  1. Hyman SE. Revolution stalled. Sci Transl Med. 2012;4(155):155cm11. 
  2. Berk M, Nierenberg AA. Three paths to drug discovery in psychiatry. Am J Psychiatry. 2015;172(5):412-4.  
  3. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry. 2015;20(2):152-3.  
  4. Berk M et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Medicine. 2013;11:200 
  5. Copeland WE, Wolke D, Lereya ST, Shanahan L, Worthman C, Costello EJ. Childhood bullying involvement predicts low-grade systemic inflammation into adulthood. Proc Natl Acad Sci USA. 2014;111(21):7570-7575.